English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/87061
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


The potential role of glycogen synthase kinase 3 inhibitors as Amyotrophic lateral sclerosis pharmacological therapy

AuthorsPalomo, Valle ; Perez, Daniel I.; Gil, Carmen ; Martínez, Ana
Issue Date2011
PublisherBentham Science Publishers
CitationCurrent Medicinal Chemistry 18: 3028- 3034 (2011)
AbstractAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons. Lately, this disease has often been related to the protein kinase called glycogen synthase kinase 3 (GSK-3), through the experimental evidence of alterations of this enzyme on ALS patients. Therefore, there have been several experimental studies using GSK-3 inhibitors, in cellular and animal models and also in clinical studies that showed the potential of the therapeutic role of these molecules. GSK-3 inhibitors might play a pivotal role in the pharmacology of ALS disease with no curative treatment nowadays. In this review we give an overview of the current research in the area, showing all the evidences of the implication of dysfunctional GSK-3 in this disease on one hand, and on the other presenting the potential role of the GSK-3 inhibitors as a future pharmacological ALS therapy. © 2011 Bentham Science Publishers Ltd.
Identifiersdoi: 10.2174/092986711796391697
issn: 0929-8673
e-issn: 1875-533X
Appears in Collections:(IQM) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.